medigraphic.com
ISSN 0016-3813 (Print)

2016, Number S2

<< Back

Gac Med Mex 2016; 152 (S2)

Historical Review of Kaposi sarcoma in pre-HAART era: evolution with different chemotherapy schedules and remission with ganciclovir use

Volkow P, Jacquemin B, Zinser JW, Pérez-Padilla R

Language: Spanish
References: 35
Page: 96-102
PDF size: 112.20 Kb.


ABSTRACT

Ganciclovir has shown in vitro anti-human herpesvirus-8 activity, Kaposi sarcoma agent. We analyzed all Kaposi sarcoma patients from 1985 to 1996 pre-HAART era and identified Kaposi sarcoma/AIDS patients who achieved complete remission prior to HAART use. Results: We saw 155 Kaposi sarcoma patients up to 1996, 150 with enough information, only 12 received ganciclovir, eight of them for ≥ 21 days; four died within 16 weeks of ganciclovir administration. We identified four male patients with extensive Kaposi sarcoma with complete remission achieved after ganciclovir for CMV end-organ disease. Complete remission was achieved (9, 5, 10 and 5 months) after ganciclovir, which persisted even after antiretroviral therapy failure. All received two nucleosides and indinavir was later added with irregular compliance. The CD4 counts when ganciclovir was started: 11 (4%), 60 (5%), 127 (14%), and 38 (3%) and when they achieved complete remission: 37 (4%), 109 (9%), 313 (13%) and 136 (9%), respectively. Two patients died with no Kaposi sarcoma relapse three years later, with wasting syndrome and other pulmonary-embolism seven years later. One was lost to follow-up in complete remission in the year 2000, the other was alive in 2014 with 27% 820 CD4 cells/ml. The use of ganciclovir was statistically significantly associated with Kaposi sarcoma remission p = 0.001. Conclusions: Ganciclovir use was associated to complete remission of Kaposi sarcoma in the pre- HAART era.


REFERENCES

  1. Barun M. Classics in oncology: idiopathic multiple pigmented sarcoma of the skin by Kaposi. CA Cancer J Clin. 1982;32:340-7.

  2. Penn I. Kaposi’s sarcoma in organ transplant recipients: report of 20 cases. Transplantation. 1979;27:8-11.

  3. Gottlieb GJ, Ragaz A, Vogel JV, et al. A preliminary communication on extensively disseminated Kaposi’s sarcoma in young homosexual men. Am J Dermatopathol. 1981;3:111-4.

  4. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, et al. Disseminated Kaposi’s sarcoma in homosexual men. Ann Intern Med. 1982;96(6 Pt 1):693-700.

  5. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865-9.

  6. Huang YQ, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi’s sarcoma. Lancet. 1995;345:759-61.

  7. Martijn JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338:948-54.

  8. Dezube BJ. Clinical presentation and natural history of AIDS-related Kaposi’s sarcoma. Hematol Oncol Clin North Am. 1996;10:1023.

  9. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS. 2000;14:987-93.

  10. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi’s sarcoma after highly active antiretroviral therapy. Mayo Clin Proc. 1998;73:439-43.

  11. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi’s sarcoma following treatment with an HIV-1 protease inhibitor. AIDS. 1997;11:261-2.

  12. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS. 2009;23:1701-6.

  13. Neyts J, Clerq E. Antiviral drug susceptibility of human herpesvirus. Antimicriob Agents Chemother. 1997;41:2754-6.

  14. Medveczky MM, Hovarth E, Lund T, Medveczky P. In vitro antiviral drug sensitivity of Kaposi´s sarcoma-associated herpes virus. AIDS. 1997;11: 1327-32.

  15. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti- herpesvirus treatment and risk of Kaposi´s sarcoma in HIV infection. AIDS. 1996;10:1101-5.

  16. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi´s sarcoma: data from Multicenter AIDS Cohort Study. J Infect Dis. 1996;173:1477-80.

  17. Badiaga S, Parola P, Zandotti C, Brouqi P. Successful treatment of Kaposi ´s sarcoma with combination of antiviral drug therapy and chemotherapy: two case reports. Clin Infect Dis. 1998;27:1558-9.

  18. Volkow PF, Cornejo P, Zinser JW, Ormsby CE, Reyes-Terán G. Life-threatening exacerbation of Kaposi’s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS. 2008;22:663-5.

  19. Gill PS, Rarick MU, Espina B, et al. Advanced acquired immune deficiency syndrome-related Kaposi’s sarcoma. Results of pilot studies using combination chemotherapy. Cancer. 1990;65:1074-8.

  20. Gompels MM, Hill A, Jenkins P, et al. Kaposi’s sarcoma in HIV infection treated with vincristine and bleomycin. AIDS. 1992;6:1175-80.

  21. Rarick MU, Gills PS, Montgomery T, Bernstein-Singer M, Jones B, Levine AM. Treatment of epidemic Kaposi´s sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine. Ann Oncol. 1990;1:147-9.

  22. Leidner RS, Aboulafia DM. Recrudescent Kaposi’s sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. 2005;19:635-44.

  23. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol. 2005;23: 5224-8.

  24. Volkow-Fernández P, Cornejo-Juárez P. Immune reconstitution inflammatory syndrome in patients with Kaposi´s sarcoma starting HAART in México. Mexico City: AIDS 2008; Abstract no. WEPE0205.

  25. Weiss RA. The conundrum of Kapsosi’s Sarcoma. Eur J Cancer. 1990;26: 657-9.

  26. Delabesse E, Oksenhendler E, Lebbé C, Vérola O, Varet B, Turhan AG. Molecular analysis of clonality in Kaposi’s sarcoma. J Clin Pathol. 1997;50:664-8.

  27. Harwood AR, Osoba D, Hofstader SL, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med. 1979;67:759-65.

  28. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary lowgrade B-cell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet. 1993;342:575-7.

  29. Raderer M, Pfeffel F, Pohl G, Mannhalter C, Vlencak J, Chott A. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut. 2000;46:133-5.

  30. Bayerdörffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue after cure of Helicobacter pylori infection. Lancet. 1995;345:1591-4.

  31. Huang GC, Sheu BS, Tsao CJ, Lin XZ, Su IJ. Eradication of Helicobacter pylori results in regression of B-cell low grade gastric MALToma with evident B-symptoms. Hepatogastroenterology. 1998;45:2464-7.

  32. Simonart T. Abatment of cutaneous Kaposi´s sarcoma associated with cidofovir treatment. Clin Infect Dis. 1998;27:1562.

  33. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117:6977-86.

  34. Grantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis. 2011;24:295-301.

  35. Tavio MG, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U. Highly active antiretroviral therapy in HIV-related Kaposi´s sarcoma. Ann Oncol. 1998;9:923.




2020     |     www.medigraphic.com